Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy.
about
Mutational analysis of the human nucleotide excision repair gene ERCC1Mechanisms of resistance to alkylating agentsCancer cell adaptation to chemotherapy.ABCC5, ERCC2, XPA and XRCC1 transcript abundance levels correlate with cisplatin chemoresistance in non-small cell lung cancer cell linesClear cell carcinoma of the ovary: molecular insights and future therapeutic perspectivesPharmacogenomics of cisplatin sensitivity in non-small cell lung cancerNuclear export of proteins and drug resistance in cancerCytotoxic and DNA-targeted therapy in urothelial cancer: have we squeezed the lemon enough?Bidirectional interconversion of stem and non-stem cancer cell populations: A reassessment of theoretical models for tumor heterogeneityChemoresistance and targeted therapies in ovarian and endometrial cancersKRAS mutation is a predictor of oxaliplatin sensitivity in colon cancer cellsExpression of base excision, mismatch, and recombination repair genes in the organogenesis-stage rat conceptus and effects of exposure to a genotoxic teratogen, 4-hydroperoxycyclophosphamideQuantification of excision repair cross-complementing group 1 and survival in p16-negative squamous cell head and neck cancersXeroderma pigmentosum group a protein and chemotherapy resistance in human germ cell tumors.Expression of genes related to activity of oxaliplatin and 5-fluorouracil in endoscopic biopsies of primary esophageal cancer in patients receiving oxaliplatin, 5-flourouracil and radiation: characterization and exploratory analysis with survival.DNA Repair Pathway Alterations in Bladder Cancer.Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burdenProstasin may contribute to chemoresistance, repress cancer cells in ovarian cancer, and is involved in the signaling pathways of CASP/PAK2-p34/actin.Role of autophagy in cisplatin resistance in ovarian cancer cellsChronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancerCombination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions.Up-regulation of Fas reverses cisplatin resistance of human small cell lung cancer cellsTumour regression and ERCC1 nuclear protein expression predict clinical outcome in patients with gastro-oesophageal cancer treated with neoadjuvant chemotherapy.Sodium arsenite and hyperthermia modulate cisplatin-DNA damage responses and enhance platinum accumulation in murine metastatic ovarian cancer xenograft after hyperthermic intraperitoneal chemotherapy (HIPEC)Establishing a panel of chemo-resistant mesothelioma models for investigating chemo-resistance and identifying new treatments for mesothelioma.A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701).Prognostic biomarkers in ovarian cancer.An ERCC1 splicing variant involving the 5'-UTR of the mRNA may have a transcriptional modulatory function.Resistance to platinum-based chemotherapy in lung cancer cell lines.C. elegans whole-genome sequencing reveals mutational signatures related to carcinogens and DNA repair deficiencyMeasuring ERCC1 protein expression in cancer specimens: validation of a novel antibody.Down-regulation of Ras-related protein Rab 5C-dependent endocytosis and glycolysis in cisplatin-resistant ovarian cancer cell lines.Oxaliplatin: a review of evolving concepts.High ERCC1 expression predicts cisplatin-based chemotherapy resistance and poor outcome in unresectable squamous cell carcinoma of head and neck in a betel-chewing area.Potential application of curcumin and its analogues in the treatment strategy of patients with primary epithelial ovarian cancer.Role of endonucleases XPF and XPG in nucleotide excision repair of platinated DNA and cisplatin/oxaliplatin cytotoxicity.Bim protein degradation contributes to cisplatin resistance.Nucleotide excision repair pathways involved in Cisplatin resistance in non-small-cell lung cancer.Expression of domains for protein-protein interaction of nucleotide excision repair proteins modifies cancer cell sensitivity to platinum derivatives and genomic stability.Part 4: pharmacogenetic variability in anticancer pharmacodynamic drug effects.
P2860
Q24324818-8C67BA52-ED94-4B03-99A1-14C35FDB8A21Q24596948-66B535B2-71F3-4349-B6B1-25273205ECD1Q24811347-9D0BBABA-DA1C-4F20-BAB8-BED75FA5EE63Q24811443-2ABF7826-72D8-4F92-B064-4F2D2F43E8E2Q26749280-EB731CA0-9494-4508-AD31-36058928BAE6Q26863490-8F6F9950-0EEC-4DE3-BE41-89E24803A81DQ27012444-4E96415B-F77E-4098-AB9A-7DC60F8ACD38Q27026717-91EF52E9-004C-4546-A064-30981CA62D7EQ28066409-376EC801-0C6B-431E-91CE-89C29BF13E48Q28073246-6DAE467D-908F-4933-A0EE-B462DFDC92C7Q28485355-1E206E11-3140-4C5A-8FA0-98F7ABDA1B97Q28569407-BF59A3DC-8CA0-484B-82E8-61B78262C4BFQ30579903-C13EF37E-C457-47FD-85D1-9451AE255BBEQ33194000-6044168D-28D4-4391-99EF-BEC22ADA6F99Q33264666-8F65EA77-3035-4F6D-A011-82FA10B8BFF3Q33607945-56B8219B-BFF7-4539-886E-201C0062B837Q33628532-34070D91-115F-48EE-AB13-A5A74DD7D7FEQ33705325-DB20D3DD-B234-46DA-86E9-1D9CDC30CD57Q33761338-326B7763-5C24-48DF-9989-C16B83EA8972Q33788519-17A8477A-D377-401A-8E5F-AFE74D450AD0Q33798999-9E9813A9-CCB5-4AE6-BBBE-13377CE99D39Q33878705-10A4FDDF-0877-4DA8-B13D-7594F86F8906Q33903723-CC8B395A-0CAA-4BBF-9C4D-145CC032EC02Q33940195-7F7E29E9-7B35-41F4-8D65-8F7086C5799AQ34072810-CF2380C3-6907-4374-B91D-453FC614F07EQ34074425-610E66F8-E638-45C8-BDF2-A8589A208ADCQ34086636-B3CB0787-C158-4182-90B8-A73F881353B1Q34106291-D9F69450-AEFB-4D13-8AA8-1770699BED1AQ34214006-DE524C61-EB9A-4119-91D5-99601B2C81D8Q34350141-14FC93B9-41E4-4389-8EFE-F5A46F7A7F83Q34408771-4B37DEAC-860C-41AE-82A5-CE9CD51043DCQ34468400-1AA8F1BD-6B9A-4499-BABE-87C00B7DC535Q34569008-8C54F9E5-9701-47A1-A45D-5E02927D2A8AQ34769944-1E620CBF-1D0C-465D-B66E-F710AC048A9BQ34833628-228A864A-E7C2-430D-8030-746C45703526Q34842777-2124FE40-EF08-4467-94D2-AB525A233463Q35063113-8A74B43C-0A16-44B8-B689-B37D34E667B4Q35198447-EDF7994C-70CC-45DE-B489-A0584CD25D3CQ35223337-910EEDFE-189F-4D5E-B955-C4733C9C65D6Q35584647-7E8949BC-0201-482D-8162-02C45E91829D
P2860
Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy.
description
1994 nî lūn-bûn
@nan
1994 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
Messenger RNA levels of XPAC a ...... o platinum-based chemotherapy.
@ast
Messenger RNA levels of XPAC a ...... o platinum-based chemotherapy.
@en
Messenger RNA levels of XPAC a ...... o platinum-based chemotherapy.
@nl
type
label
Messenger RNA levels of XPAC a ...... o platinum-based chemotherapy.
@ast
Messenger RNA levels of XPAC a ...... o platinum-based chemotherapy.
@en
Messenger RNA levels of XPAC a ...... o platinum-based chemotherapy.
@nl
prefLabel
Messenger RNA levels of XPAC a ...... o platinum-based chemotherapy.
@ast
Messenger RNA levels of XPAC a ...... o platinum-based chemotherapy.
@en
Messenger RNA levels of XPAC a ...... o platinum-based chemotherapy.
@nl
P2093
P2860
P356
P1476
Messenger RNA levels of XPAC a ...... o platinum-based chemotherapy.
@en
P2093
P2860
P304
P356
10.1172/JCI117388
P407
P577
1994-08-01T00:00:00Z